(MedPage Today) — BERLIN — After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.
KEYNOTE-B96 enrolled patients…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118021
Author :
Publish date : 2025-10-19 18:10:00
Copyright for syndicated content belongs to the linked Source.
